(not disclosed)
Every deal, price, and strategic rationale.
Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.
Three patterns show up across Danaher's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.
Every major acquisition announcement references DBS as the operational toolkit applied to acquired businesses — a system of lean manufacturing, growth tools, and management standardization that Danaher deploys to drive margin expansion and accelerated organic growth. Beckman Coulter targeted $250 million in cost synergies delivered via DBS over 18-24 months; the same playbook applied to Pall ($300M) and the GE BioPharma carve-out.
Danaher's $13.6B Pall and $21.4B GE Biopharma/Cytiva acquisitions weren't bolt-ons — they were intentional platform-defining bets that re-anchored Life Sciences as Danaher's biggest segment. The pattern: identify a global #1 or #2 in a structurally growing segment (filtration, bioprocessing, diagnostics), pay premium multiples, then deploy DBS to compound the cash flow upward.
Danaher has repeatedly executed via tender offers (Sybron $47/share, Beckman $83.50/share, Tektronix $38/share, Masimo) and complex carve-outs (Cytiva from GE Healthcare). The willingness to absorb tender-offer complexity and carve-out separation costs gives Danaher access to assets — and pricing leverage — that strategics with less integration capability would avoid.
41 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
Global leader in breast biopsy instruments and consumables (Mammotome)...
(not disclosed)
Chilean water treatment solutions provider; founded 1961.
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
(not disclosed)
Every figure on this page was synthesized by VectorShift from SEC EDGAR filings — before an analyst would finish their first coffee. Point the same pipeline at private deal documents and the output is the same.
Every figure on this page came from public filings. Point the same pipeline at the documents your team actually works on — CIMs, management decks, expert calls, portfolio reports — and get research like this in minutes, not weeks.